Results 241 to 250 of about 11,371 (259)
Some of the next articles are maybe not open access.
A fatal overdose of the ergot derivative cabergoline
Forensic Science International, 2004A 79-year-old woman, with Parkinson's disease treated with cabergoline, was admitted to a hospital due to jaundice and weakness. She was found confused, absent minded, and died after 2 weeks. Autopsy showed an extrahepatic bile duct adenocarcinoma with spread to the gall bladder, the liver, and regional lymphnodes. While cleaning the hospital bed after
Johansen, Sys Stybe +1 more
openaire +3 more sources
Effect of cabergoline on thyroid function in hyperprolactinaemia [PDF]
Clinical Endocrinology, 2002 The definitive version is available at onlinelibrary.wiley.com ; M.A. Keogh and G.A.
Keogh, M., Wittert, G.
openaire +3 more sources
Aortic regurgitation associated with cabergoline therapy
British Journal of Hospital Medicine, 2008A 57-year-old man with a history of Lewy body dementia was referred for cardiac assessment with a history of exertional dyspnoea and orthopnoea. Symptoms developed 12 months after commencement of cabergoline by his neurologist. Transoesophageal echo demonstrated aortic regurgitation, which was moderate by vena contracta (0.6 cm) (Figure 1). The aortic
Danny Flannery, Kristopher Lyons
openaire +3 more sources
TSH-secreting adenoma improved with cabergoline
Annales d'Endocrinologie, 2008TSH-secreting adenomas are rare tumors, representing only 0.5 to 2.5% of pituitary adenomas. Their main clinical characteristics include signs of thyrotoxicosis, diffuse goiter and a compressive syndrome. Biologically, free T4 and T3 serum levels are elevated, contrasting with inadequate serum TSH levels and increased alpha chains.
Serge Blond +8 more
openaire +3 more sources
Endocrinology: Cabergoline: a new drug for the treatment of hyperprolactinaemia
Human Reproduction, 1995Recent clinical studies performed with the novel long acting dopamine agonist cabergoline in the inhibition and suppression of puerperal lactation and in the treatment of hyperprolactinaemic disorders are reviewed. Inhibition of puerperal lactation is achieved with a single 1.0 mg oral administration of the drug, with better efficacy and tolerability ...
Carlo Ferrari +2 more
openaire +3 more sources
Treatment of Macroprolactinoma With Cabergoline
The Journal of Urology, 1997OBJECTIVE Cabergoline is now established as an effective and well‐tolerated treatment for prolactinoma. However, there are relatively few published data on the treatment of macro‐, as opposed to micro‐, prolactinoma. We have therefore reviewed the efficacy and safety of cabergoline in the treatment of patients with prolactin‐secreting macroadenomas ...
Ferrari, C.I. +10 more
openaire +4 more sources
Pituitary apoplexy associated with cabergoline therapy
Journal of Clinical Neuroscience, 2013Pituitary apoplexy is a rare medical emergency which results from hemorrhage or infarction in the pituitary gland. One of the predisposing factors is treatment with dopamine agonists, especially bromocriptine. We report a 20-year-old Chinese man with prolactinoma who developed pituitary apoplexy 6 weeks after initiation of cabergoline.
Edwin Chng, Rinkoo Dalan
openaire +3 more sources
Cabergoline for preventing ovarian hyperstimulation syndrome
2010Ovarian hyperstimulation syndrome (OHSS) is a complication resulting from administration of human chorionic gonadotrophin (hCG) in assisted reproduction technology (ART) treatment. Most case are mild, but forms of moderate or severe OHSS appear in 3% to 8% of in vitro fertilisation (IVF) cycles.
Roger Hart +5 more
openaire +3 more sources